A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic and Wegovy, falsely claim they are FDA-approved.
13d
New research published in JAMA Network Open led by Truveta Research and Ezekiel Emanuel, MD, PhD, Perelman School of Medicine ...
HealthDay News — The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, ...
Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...
The beverage giant is ready to manage, mitigate and adjust to the “dynamic macro environment,” including potential tariffs ...
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...
News Medical on MSN9d
High discontinuation rates of GLP-1 agonists found among patients with obesityDiscontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...
Greater weight loss was linked to lower discontinuation rates, with a 1% reduction in weight lowering the hazard of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback